This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Multiple sclerosis
  • /
  • Association of British Neurologists: revised (2015...
Guideline

Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis

Read time: 1 mins
Last updated:22nd Jun 2015

This 2015 revised guideline replaces former versions. It includes all newly approved or licensed treatments for MS and represents a consensus concerning their use. These guidelines will require future revision as other treatments receive approval (eg, daclizumab and ocrelizumab): we suggest they are reviewed after an interval of no longer than 12 months. The guideline is not intended to provide a complete description of the possible complications and monitoring of disease-modifying treatments in MS; we refer prescribing neurologists to the relevant summaries of product characteristics.

Read full guideline